• Author
    Posts
  • #9011272
    Cold Email
    Ohimai Unoje
    Participant
    Apr 27, 2023

    Hi everyone, I’d love to get some feedback on am email I’m sending out. The target audience is physicians and oncologists that are working on drug resistance and relapse in cancer patients.

    Draft #1:

    Good morning Dr ——- ,

    A friend of mine sent me your latest paper (https://pubmed.ncbi.nlm.nih.gov/37068173/) after seeing the presentation at AACR.
    I have seen more and more physicians using Single Cell Analysis to study their patients samples further to see what mutational co-occurrence is happening at the cellular level.
    In 2021, Dr Piro Lito (MSKCC) used that approach to map resistance mechanisms in KRAS G12Ci treated PDX models (Diverse alterations associated with resistance to KRAS(G12C) inhibition – Nature). Now he’s able to test with 100% certainty how this patient’s tumors are evolving in response to specific therapies.
    I’ll be at XXXXXXX today and tomorrow for a series of meetings, would it make sense for a brief meeting to see if this same approach can help identify other co-occurring mutations in this cohort that are clinically relevant but below the LOD of bulk sequencing?
    Thanks
    -Ohi

    Draft #2:

    Hi Dr X,
    A colleague sent me your latest paper after seeing your presentation at AACR.
    Dr Piro Lito (MSKCC) used our technology to map resistance mechanisms in KRAS G12Ci treated PDX models.
    He’s able to test with 100% certainty how this patient’s tumors are evolving in response to specific therapies
    I’ve meetings at XXXXXXX today and tomorrow.
    Would it make sense for me to stop by and see if our technology could be helpful in the next phase of your trial?
    Thanks
    Ohi
    #9011283
    Lauren Bailey
    Participant
    Apr 27, 2023
    Lauren Bailey Apr 27, 2023

    Hi Dr X, A colleague sent me your latest paper after seeing your presentation at AACR. Dr Piro Lito (MSKCC) used our technology to map resistance mechanisms in KRAS G12Ci treated PDX models. He’s able to test with 100% certainty how this patient’s tumors are evolving in response to specific therapies I’ve meetings at XXXXXXX today and tomorrow. Would it make sense for me to stop by and see if our technology could be helpful in the next phase of your trial? Thanks Ohi

    That looks like a strong email to me! I wish my product was so specific!

    #9011296
    Jan Oda-Biro
    Participant
    May 8, 2023
    Jan Oda-Biro May 8, 2023

    Did you book meetings with this Ohi? I’m also selling medical devices and I’ve never sent what looks like a ‘technical’ email before. If you got results, I’ll try the same.

    #9011300
    Ohimai Unoje
    Participant
    May 8, 2023
    Ohimai Unoje May 8, 2023

    Yes. But very low frequency. 25 email sent and 1 meeting booked.
    Definitely need to tweak it a bit

  • You must be logged in to reply to this topic.